Company Filing History:
Years Active: 2019-2022
Title: Wilfried Roth: Innovator in Cancer Treatment and Tumor Prognosis
Introduction
Wilfried Roth is a notable inventor based in Schwetzingen, Germany. He has made significant contributions to the field of cancer treatment and tumor prognosis through his innovative patents. With a total of two patents to his name, Roth's work focuses on enhancing therapeutic strategies for cancer patients.
Latest Patents
Roth's latest patents include a combined preparation of PKM2 modulators and HMGB1. This invention relates to a combined preparation that comprises a modulator of pyruvate kinase M2 (PKM2) activity and an agent providing high mobility group box 1 (HMGB1) polypeptide or a derivative thereof. The combined preparation is intended for use as a medicament in treating inappropriate cellular proliferation, particularly in cancer. Additionally, Roth has developed a diagnostic method for tumor energy metabolism profiling. This method predicts tumor prognosis, including the likelihood of metastasis or relapse, by determining the enzyme activity of key enzymes in fresh tumor tissue after incubation.
Career Highlights
Throughout his career, Wilfried Roth has worked with prestigious institutions such as Ruprecht-Karls-Universität Heidelberg and Universität Heidelberg. His research has focused on the intersection of cancer biology and therapeutic innovation, leading to advancements in treatment methodologies.
Collaborations
Roth has collaborated with notable colleagues, including Georg Gdynia and Sven Sauer. These partnerships have contributed to the development of his innovative patents and research initiatives.
Conclusion
Wilfried Roth's contributions to cancer treatment and tumor prognosis through his patents highlight his role as an influential inventor in the medical field. His work continues to pave the way for advancements in therapeutic strategies for cancer patients.